What is CBLL's health score?

Ceribell, Inc. (CBLL) has a TradeApes health score of 43 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is CBLL's estimated fair value?

Based on our 5-year discounted cash flow model, Ceribell, Inc.'s estimated fair value is $5.3 per share, representing a -71.8% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is CBLL undervalued or overvalued?

Our model currently rates CBLL as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for CBLL... Refresh in a moment for the full analysis.

Ceribell, Inc. (CBLL)

Healthcare Overvalued low weak

$18.75

Updated: 2026-06-05

TradeApes Score

Financial Strength

35 Weak

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

40 Weak

Risk

80 Strong

Est. Fair Value $5.3

DCF Upside -71.8%

Sector Rank #898 of 6550

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.